Emergent BioSolutions Inc. (EBS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EBS Revenue Growth
Revenue Breakdown (FY 2025)
EBS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EBS Revenue Analysis (2014–2025)
As of May 8, 2026, Emergent BioSolutions Inc. (EBS) generated trailing twelve-month (TTM) revenue of $742.9 million, reflecting significant decline in growth of -23.6% year-over-year. The most recent quarter (Q4 2025) recorded $148.7 million in revenue, down 35.7% sequentially.
Looking at the longer-term picture, EBS's 5-year compound annual growth rate (CAGR) stands at -14.0%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $1.77 billion in 2021.
Revenue diversification analysis shows EBS's business is primarily driven by Product (95%), and Contracts and Grants (5%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SIGA (-22.1% YoY), PRGO (-3.6% YoY), and BRKR (+0.4% YoY), EBS has underperformed the peer group in terms of revenue growth. Compare EBS vs SIGA →
EBS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EBSCurrent | $743M | -23.6% | -14.0% | 14.8% | |
 SIGA | $95M | -22.1% | -5.4% | 25.1% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 BRKR | $3.4B | +0.4% | +11.6% | 6.9% | |
 ABCL | $75M | +160.5% | -20.3% | -289.0% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% |
EBS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $742.9M | -28.8% | $350.6M | 47.2% | $110.2M | 14.8% |
| 2024 | $1.04B | -0.5% | $375.4M | 36.0% | $-108,700,000 | -10.4% |
| 2023 | $1.05B | -6.1% | $360.0M | 34.3% | $-726,400,000 | -69.2% |
| 2022 | $1.12B | -37.0% | $473.0M | 42.3% | $-170,000,000 | -15.2% |
| 2021 | $1.77B | +12.4% | $793.2M | 44.7% | $341.4M | 19.2% |
| 2020 | $1.58B | +42.6% | $863.1M | 54.7% | $438.5M | 27.8% |
| 2019 | $1.11B | +41.4% | $483.1M | 43.7% | $114.1M | 10.3% |
| 2018 | $782.4M | +39.5% | $320.4M | 41.0% | $89.8M | 11.5% |
| 2017 | $560.9M | +14.8% | $283.6M | 50.6% | $124.3M | 22.2% |
| 2016 | $488.8M | -0.1% | $244.8M | 50.1% | $105.5M | 21.6% |
See EBS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EBS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EBS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEBS — Frequently Asked Questions
Quick answers to the most common questions about buying EBS stock.
Is EBS's revenue growth accelerating or slowing?
EBS revenue declined -23.6% year-over-year, contrasting with the 5-year CAGR of -14.0%. TTM revenue fell to $743M. This reverses the prior growth trend.
What is EBS's long-term revenue growth rate?
Emergent BioSolutions Inc.'s 5-year revenue CAGR of -14.0% reflects the variable expansion pattern. Current YoY growth of -23.6% is below this long-term average.
How is EBS's revenue distributed by segment?
EBS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.